OpenURL Connection Search

Select item for more details and to access through your institution.

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Published in:
Multiple Sclerosis Journal, 2021, v. 27, n. 6, p. 883, doi. 10.1177/1352458520937282
By:
- Longbrake, Erin E;
- Mao-Draayer, Yang;
- Cascione, Mark;
- Zielinski, Tomasz;
- Bame, Eris;
- Brassat, David;
- Chen, Chongshu;
- Kapadia, Shivani;
- Mendoza, Jason P;
- Miller, Catherine;
- Parks, Becky;
- Xing, Diana;
- Robertson, Derrick
Publication type:
Article
Publication Rate of Podium Presentations From the North American Spine Society Annual Meetings.
Published in:
Global Spine Journal, 2018, v. 8, n. 3, p. 273, doi. 10.1177/2192568217713732
By:
- Raudenbush, Brandon;
- Frost, Chelsea;
- Okafor, Richard;
- Chongshu Chen;
- Xing Qui;
- Mesfin, Addisu
Publication type:
Article
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy.
Published in:
European Journal of Heart Failure, 2024, v. 26, n. 2, p. 397, doi. 10.1002/ejhf.3138
By:
- Garcia‐Pavia, Pablo;
- Grogan, Martha;
- Kale, Parag;
- Berk, John L.;
- Maurer, Mathew S.;
- Conceição, Isabel;
- Di Carli, Marcelo;
- Solomon, Scott D.;
- Chen, Chongshu;
- Yureneva, Elena;
- Vest, John;
- Gillmore, Julian D.
Publication type:
Article
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
Published in:
Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420915005
By:
- Gold, Ralf;
- Arnold, Douglas L.;
- Bar-Or, Amit;
- Fox, Robert J.;
- Kappos, Ludwig;
- Chen, Chongshu;
- Parks, Becky;
- Miller, Catherine
Publication type:
Article
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE.
Published in:
Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420915005
By:
- Gold, Ralf;
- Arnold, Douglas L.;
- Bar-Or, Amit;
- Fox, Robert J.;
- Kappos, Ludwig;
- Chongshu Chen;
- Parks, Becky;
- Miller, Catherine
Publication type:
Article
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Published in:
Neurology & Therapy, 2023, v. 12, n. 5, p. 1759, doi. 10.1007/s40120-023-00522-4
By:
- Obici, Laura;
- Ajroud-Driss, Senda;
- Lin, Kon-Ping;
- Berk, John L.;
- Gillmore, Julian D.;
- Kale, Parag;
- Koike, Haruki;
- Danese, David;
- Aldinc, Emre;
- Chen, Chongshu;
- Vest, John;
- Adams, David;
- the HELIOS-A Collaborators Study Group;
- Wixner, Jonas;
- Backlund, Rolf;
- Pilebro, Björn;
- Anan, Intissar;
- Edbom, Fredrik;
- Ekman, Anna;
- Arvidsson, Sandra
Publication type:
Article

Found: 6

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.

Publication Rate of Podium Presentations From the North American Spine Society Annual Meetings.

Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy.

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE.

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.